|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00076011 |
Purpose
The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
| Condition | Intervention | Phase |
|
Kidney Neoplasms |
Drug: VEGFR and PDGFR inhibitor |
Phase II |
| MedlinePlus related topics: | Cancer Kidney Cancer |
| Drug Information available for: | Axitinib |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Phase 2 Study of AG 013736 as Second-Line Treatment in Patients With Metastatic Renal Cell Cancer |
| Estimated Enrollment: | 52 |
| Study Start Date: | October 2003 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |||||
| Pfizer Investigational Site | |||||
| San Francisco, California, United States, 94115 | |||||
| United States, Massachusetts | |||||
| Pfizer Investigational Site | |||||
| Boston, Massachusetts, United States, 02114 | |||||
| Pfizer Investigational Site | |||||
| Boston, Massachusetts, United States, 02115 | |||||
| United States, New York | |||||
| Pfizer Investigational Site | |||||
| New York, New York, United States, 10021 | |||||
| United States, Ohio | |||||
| Pfizer Investigational Site | |||||
| Cleveland, Ohio, United States, 44195 | |||||
| United States, Pennsylvania | |||||
| Pfizer Investigational Site | |||||
| Philadelphia, Pennsylvania, United States, 19111-2497 | |||||
| United States, Wisconsin | |||||
| Pfizer Investigational Site | |||||
| Madison, Wisconsin, United States, 53792 | |||||
| France, Paris | |||||
| Pfizer Investigational Site | |||||
| Paris Cedex 13, Paris, France, 75651 | |||||
| Germany | |||||
| Pfizer Investigational Site | |||||
| 30625 Hannover, Germany | |||||
| Pfizer |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
To obtain contact information for a study center near you, click here. 
  |
| Study ID Numbers: | A4061012 |
| First Received: | January 12, 2004 |
| Last Updated: | August 14, 2007 |
| ClinicalTrials.gov Identifier: | NCT00076011 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|